FDA urged by pro‑life doctors to restore in‑person abortion pill rule

A group of pro‑life physicians representing tens of thousands of medical professionals sent a letter to Acting FDA Commissioner Kyle Diamantasto asking that the agency reinstate the in‑person dispensing requirement for the abortion pill mifepristone. The requirement, removed during the Biden administration’s COVID‑era policy changes, is argued to be essential for patient safety.

The doctors cite new data indicating serious complication rates far higher than previously disclosed, including hemorrhage, sepsis and incomplete abortions. Between 2017 and 2023, more than 860,000 adverse events were reported after mifepristone use, with over 10% classified as severe. The letter calls for a comprehensive safety review, mandatory reporting of adverse events, and the use of ultrasounds to confirm gestational age before prescribing the drug.